Featured Research

from universities, journals, and other organizations

Gene variations linked to intestinal blockage in newborns with cystic fibrosis

Date:
April 1, 2012
Source:
University of North Carolina at Chapel Hill School of Medicine
Summary:
The discovery by cystic fibrosis researchers offers the possibility of developing therapies to intervene in utero. Some of these genes may influence disease in other cystic fibrosis-affected organs.

University of North Carolina at Chapel Hill researchers working as part of the International Cystic Fibrosis Consortium have discovered several regions of the genome that may predispose cystic fibrosis (CF) patients to develop an intestinal blockage while still in the uterus.

A report of this international study appears online April 1, 2012 in the journal Nature Genetics. It was the work of the North America CF Gene Modifier Consortium, which brought together dozens of investigators from the United States, Canada, and from France, to identify genetic variations that could be linked with meconium ileus (MI), an intestinal obstruction that usually requires emergency surgery for treatment, and can result in a substantially increased rate of serious health problems.

MI affects roughly 15-20 percent of all patients with CF, a genetic condition that causes scarring throughout the body, especially the lungs and pancreas. Though every CF patient carries mutations in both copies of the same gene -- coding for a protein called cystic fibrosis transmembrane conductance regulator, or CFTR -- symptoms can vary widely from patient to patient.

The genome-wide association study (GWAS) of more than 3,700 CF patients identified non-CFTR genetic variants in the cell membrane that separates the interior of cells from the outside environment. More specifically, the variants involved genes responsible for ion transport in the lower end of the small intestine.

"These variants involve cells in the small intestine that predispose CF patients to develop MI while still in the womb," said one of the senior study authors Michael Knowles, MD, professor of pulmonary and critical care medicine at UNC and a member of UNC's Cystic Fibrosis-Pulmonary Research and Treatment Center.

"The discovery provides new understanding of the pathogenic mechanisms underlying MI. In addition, it offers the possibility of developing therapies to intervene in utero," Knowles said. "Further, it provides molecular insight into the role of genetic variation in ion transporters in CF, which may be applicable to more commonly, and severely, involved organs such as the lungs."

Other UNC study coauthors are Wanda K. O'Neal, Rhonda G. Pace, Jaclyn R. Stonebraker, Sally D. Wood, and Fred A. Wright. In the U.S., the study was funded by the National Heart, Lung and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, and the U.S. Cystic Fibrosis Foundation.


Story Source:

The above story is based on materials provided by University of North Carolina at Chapel Hill School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lei Sun, Johanna M Rommens, Harriet Corvol, Weili Li, Xin Li, Theodore A Chiang, Fan Lin, Ruslan Dorfman, Pierre-Franηois Busson, Rashmi V Parekh, Diana Zelenika, Scott M Blackman, Mary Corey, Vishal K Doshi, Lindsay Henderson, Kathleen M Naughton, Wanda K O'Neal, Rhonda G Pace, Jaclyn R Stonebraker, Sally D Wood, Fred A Wright, Julian Zielenski, Annick Clement, Mitchell L Drumm, Pierre-Yves Boλlle, Garry R Cutting, Michael R Knowles, Peter R Durie, Lisa J Strug. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nature Genetics, 2012; DOI: 10.1038/ng.2221

Cite This Page:

University of North Carolina at Chapel Hill School of Medicine. "Gene variations linked to intestinal blockage in newborns with cystic fibrosis." ScienceDaily. ScienceDaily, 1 April 2012. <www.sciencedaily.com/releases/2012/04/120401134927.htm>.
University of North Carolina at Chapel Hill School of Medicine. (2012, April 1). Gene variations linked to intestinal blockage in newborns with cystic fibrosis. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/04/120401134927.htm
University of North Carolina at Chapel Hill School of Medicine. "Gene variations linked to intestinal blockage in newborns with cystic fibrosis." ScienceDaily. www.sciencedaily.com/releases/2012/04/120401134927.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins